Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | CEO, President & Director | 986.32k | -- | 1962 |
| Mr. Johannes Van Houte | Chief Financial Officer | 681.98k | -- | 1966 |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer | 702.75k | -- | 1971 |
| Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Dr. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Rita Kwong | Senior Accounting Manager | -- | -- | -- |
| Dr. Pasit Phiasivongsa Ph.D. | Chief Technical Officer | -- | -- | -- |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer | 595.83k | 599.89k | 1965 |
| Dr. Jason Kantor Ph.D. | Chief Business Officer | -- | -- | -- |
| Mr. Christopher B. Phelps Ph.D. | Senior VP & Head of Early Drug Discovery | -- | -- | -- |
Nurix Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 286
Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Corporate Governance
Upcoming Events
April 8, 2025 at 12:30 PM UTC - April 14, 2025 at 12:30 PM UTC
Nurix Therapeutics, Inc. Earnings Date